Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Concert Pharmaceuticals
This study will evaluate the safety and tolerability of treatment with CTP-499 starting with 600 milligrams (mg) once a day (QD) for 2 weeks followed by 600 mg twice a day (BID) for 2 weeks in non-dialysis patients associated with moderate chronic kidney disease defined as an estimated Glomerular Filtration Rate or eGFR that is 30-59 mL/min/1.73m2
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient has a diagnosis of chronic kidney disease
If taking antihypertensive and antidiabetes medications, regimen must be stable for a minimum of 4 weeks
Patient has systolic blood pressure less than or equal to 160 mm Hg and diastolic blood pressure less than or equal to 95 mm Hg
You may not be if
Patient has concurrent condition such as uncontrolled inflammatory disease, acute infection or clinically unstable autoimmune, endocrine, neurological, psychiatric, retinal, cardiovascular, bronchopulmonary, hepatic, gastrointestinal or musculoskeletal disorder
Patient has acute, active and/or current unstable renal impairment disease
Patient has been hospitalized for acute renal failure in the past year
Patient has active malignancy or a history of neoplastic disease
Patient has QTc interval \> 450 milliseconds
Patient is currently on cytotoxic or other immunosuppressive therapy
Clareo Health | Safety & Tolerability Study of CTP-499 in Patients With Moderate Chronic Kidney Disease
